Oncology

Oncology Review CME / CPD 

Full Course:  20 AMA PRA Category 1 Credits for CME / CEU / CPD

Short Course:  10 AMA PRA Category 1 Credits for CME / CEU / CPD

Course(s) are appropriate for:   Family Practitioners, Pediatricians, Internists, General Practitioners, Nurses, Nurse Practitioners, Physician Assistants (PA-C's)

Series 35 (ONC35) Topics Include:  Leukemia, Research Updates, Sarcomas, Palliative and Supportive Care, Hematologic Malignancies, and more.

To view topic outline of the full or short course, select the Course Type (Full or Short) below:

Format:
Available in Audio format.

Course Topics

Research Updates from the 11th International Symposium on Regional Cancer Therapies

Assess the utility of systemic chemotherapy in patients who have undergone ablation of a small hepatocellular carcinoma; Compare outcomes of isolated limb perfusion to those of isolated limb infusion for the treatment of melanoma; Explain the role of mucins in cancer; List mutations commonly found in peritoneal metastases of gastrointestinal tumors; Identify factors that influence survival of patients with dual-cavity mesothelioma.

Leukemia/Cancer Survivors

Recognize which of the leukemias and their complications are considered true medical emergencies; Characterize different types of leukemias based on presentation and peripheral blood or bone marrow findings; Identify the indications for immediate oncology referral or evaluation in a patient with leukemia; Recommend lifestyle choices to enhance the quality of life of cancer survivors; Improve surveillance for recurrence of cancer.

Advances in Immunotherapy and Hormonal Therapy

Select appropriate immunotherapy for bladder cancer; Explain the benefit of adding entinostat to interleukin-2 in the treatment of renal cell carcinoma; Consider sipuleucel-T for the treatment of prostate cancer; Recognize the significance of mutations of ESR1 in the treatment of breast cancer; Compare immunotherapeutic drugs used to treat breast cancer.

Hematologic Malignancies

Summarize favorable and unfavorable cytogenetic profiles observed in patients with myelodysplastic syndrome; List risks and benefits of drugs and antibodies commonly used to manage myelodysplastic syndrome; Counsel a patient with myelodysplastic syndrome who is contemplating stem cell transplantation; Weigh the risks and benefits of drugs and regimens commonly used to treat Waldenstrom macroglobulinemia; Assess the efficacy of ibrutinib for treatment of Waldenstrom macroglobulinemia.

Highlights from the 13th International Ultmann Chicago Lymphoma Symposium, Part 1

Compare risk-stratification schema used for patients with HL; Choose appropriate treatment for patients with HL; Recognize the role of positron emission tomography in the management of HL; Manage adverse events associated with brentuximab vedotin and checkpoint inhibitors; Explain the importance of programmed death-ligands in HL.

Cancer Therapy Review

Identify molecular targets for treatment of non-small cell lung cancer; Choose appropriate strategies for identifying mutations that can be targeted in the treatment of non-small cell lung cancer; Select therapies for cancer based on new indications approved by the US Food and Drug Administration; Determine whether patients are appropriate candidates for use of novel cancer treatment agents; Consider the use of checkpoint inhibitors for newly expanded cancer indications.

Highlights from the 13th Annual Ultmann Chicago Lymphoma Symposium, Part 2

Recognize the effect of ethnicity on the feasibility of finding matched stem cell donors; Compare the outcomes of allogeneic stem cell transplantation with various graft sources; Select appropriate treatment of cutaneous T-cell lymphoma (CTCL) based on stage of disease; Assess the benefits of low-dose total-skin electron beam therapy in CTCL; Evaluate data on targeted therapies under investigation for the treatment of CTCL.

Thyroid Cancer

Review the epidemiology of anaplastic thyroid cancer; Apply National Comprehensive Cancer Network and American Thyroid Association guidelines for the diagnosis and management of anaplastic thyroid cancer; Evaluate the use of the tyrosine kinase inhibitors sorafenib and lenvatinib for patients with thyroid cancer; Consider new therapies, including immune checkpoint inhibitors, for the treatment of thyroid cancer; Interpret cytology and pathology reports for patients with thyroid disease.

Palliative and Supportive Care in Oncology

Recommend lifestyle changes that will decrease the risk for chemotherapy-induced peripheral neuropathy (CIPN); Recognize the importance of age in the development of CIPN; Choose appropriate drugs to prevent chemotherapy-induced nausea and vomiting (CINV); Describe the pathways responsible for emesis in CINV; Explain the role of lifestyle modifications in the management of a patient with cancer.

Sarcomas and Brain Tumors/Malignant Melanomas and Skin Cancers

Recognize the prognostic significance of molecular markers of brain tumors; Assess data on the use of temozolomide in the treatment of brain tumors; Compare data on treatments available for sarcomas; Summarize the results achieved in trials of programmed-cell death protein-1 in melanoma; Anticipate adverse events experienced by patients receiving treatment for melanoma.

QUALIFIES FOR END OF LIFE/PALLIATIVE CARE

Research Updates from the 11th International Symposium on Regional Cancer Therapies

Assess the utility of systemic chemotherapy in patients who have undergone ablation of a small hepatocellular carcinoma; Compare outcomes of isolated limb perfusion to those of isolated limb infusion for the treatment of melanoma; Explain the role of mucins in cancer; List mutations commonly found in peritoneal metastases of gastrointestinal tumors; Identify factors that influence survival of patients with dual-cavity mesothelioma.

Leukemia/Cancer Survivors

Recognize which of the leukemias and their complications are considered true medical emergencies; Characterize different types of leukemias based on presentation and peripheral blood or bone marrow findings; Identify the indications for immediate oncology referral or evaluation in a patient with leukemia; Recommend lifestyle choices to enhance the quality of life of cancer survivors; Improve surveillance for recurrence of cancer.

Highlights from the 13th International Ultmann Chicago Lymphoma Symposium, Part 1

Compare risk-stratification schema used for patients with HL; Choose appropriate treatment for patients with HL; Recognize the role of positron emission tomography in the management of HL; Manage adverse events associated with brentuximab vedotin and checkpoint inhibitors; Explain the importance of programmed death-ligands in HL.

Highlights from the 13th Annual Ultmann Chicago Lymphoma Symposium, Part 2

Recognize the effect of ethnicity on the feasibility of finding matched stem cell donors; Compare the outcomes of allogeneic stem cell transplantation with various graft sources; Select appropriate treatment of cutaneous T-cell lymphoma (CTCL) based on stage of disease; Assess the benefits of low-dose total-skin electron beam therapy in CTCL; Evaluate data on targeted therapies under investigation for the treatment of CTCL.

Palliative and Supportive Care in Oncology

Recommend lifestyle changes that will decrease the risk for chemotherapy-induced peripheral neuropathy (CIPN); Recognize the importance of age in the development of CIPN; Choose appropriate drugs to prevent chemotherapy-induced nausea and vomiting (CINV); Describe the pathways responsible for emesis in CINV; Explain the role of lifestyle modifications in the management of a patient with cancer.

Advances in Immunotherapy and Hormonal Therapy

Select appropriate immunotherapy for bladder cancer; Explain the benefit of adding entinostat to interleukin-2 in the treatment of renal cell carcinoma; Consider sipuleucel-T for the treatment of prostate cancer; Recognize the significance of mutations of ESR1 in the treatment of breast cancer; Compare immunotherapeutic drugs used to treat breast cancer.

Hematologic Malignancies

Summarize favorable and unfavorable cytogenetic profiles observed in patients with myelodysplastic syndrome; List risks and benefits of drugs and antibodies commonly used to manage myelodysplastic syndrome; Counsel a patient with myelodysplastic syndrome who is contemplating stem cell transplantation; Weigh the risks and benefits of drugs and regimens commonly used to treat Waldenstrom macroglobulinemia; Assess the efficacy of ibrutinib for treatment of Waldenstrom macroglobulinemia.

Cancer Therapy Review

Identify molecular targets for treatment of non-small cell lung cancer; Choose appropriate strategies for identifying mutations that can be targeted in the treatment of non-small cell lung cancer; Select therapies for cancer based on new indications approved by the US Food and Drug Administration; Determine whether patients are appropriate candidates for use of novel cancer treatment agents; Consider the use of checkpoint inhibitors for newly expanded cancer indications.

Thyroid Cancer

Review the epidemiology of anaplastic thyroid cancer; Apply National Comprehensive Cancer Network and American Thyroid Association guidelines for the diagnosis and management of anaplastic thyroid cancer; Evaluate the use of the tyrosine kinase inhibitors sorafenib and lenvatinib for patients with thyroid cancer; Consider new therapies, including immune checkpoint inhibitors, for the treatment of thyroid cancer; Interpret cytology and pathology reports for patients with thyroid disease.

Sarcomas and Brain Tumors/Malignant Melanomas and Skin Cancers

Recognize the prognostic significance of molecular markers of brain tumors; Assess data on the use of temozolomide in the treatment of brain tumors; Compare data on treatments available for sarcomas; Summarize the results achieved in trials of programmed-cell death protein-1 in melanoma; Anticipate adverse events experienced by patients receiving treatment for melanoma.

QUALIFIES FOR END OF LIFE/PALLIATIVE CARE

Additional Information

Additional Continuing Medical Education options available:

Other courses of interest may include:  SurgeryFamily PracticeInternal MedicineObesity and Nutrition.

If you have taken the current Oncology CME / CPD Review listed above or if you are seeking additional credits, please visit: Medical Courses Coming Soon There you will find abbreviated listings of additional courses available related to this specialty and courses that are soon to be released.

For over 30 years, ASI has provided Continuing Medical Education, CME & CEU and Continuing Professional Development Education (CPD) for physicians and allied professionals in Oncology plus over 40 other specialties and subspecialties.  Lectures are recorded annually at the top seminars and conferences to provide the most current medical education to our clients.